How many acquisitions has Gilead made so far?

Gilead has completed 21 acquisitions so far, with an average acquisition amount of $3.33B.

Which countries does Gilead usually acquire in?

Gilead has made acquisitions in 5 countries with the most activity in United States and Germany.

Which is Gilead's latest acquisition?

Gilead's most recent acquisition is Tubulis Technologies, a Developer of antibody-drug conjugates for the treatment of cancer, acquired in April 2026.

Which sectors does Gilead target for acquisitions?

Most of Gilead's acquisitions are in Oncology (14) and Immunotherapy (8).

List of 21 Acquisitions by Gilead (Jul 2026)

Gilead has made a total of 21 acquisitions. It has completed these across 11 sectors, including Oncology, Immunotherapy, and Infectious Diseases, spanning 5 countries, notably United States, Germany, and United Kingdom. Peak activity occurred in 2026, 2020, and 2017, with 3, 3, and 2 acquisitions, respectively. The average number of acquisitions per year between 2020 and 2025 is 0.6, and 3 acquisitions have been completed in the current calendar year. The most recent acquisition, finalized in April 2026, is Tubulis Technologies, a Munich-based developer of antibody-drug conjugates for cancer treatment founded in 2015.

Here's the year on year acquisition history of Gilead:

Number of Total Acquisitions

Year	# Acquisitions
2026	3
2024	1
2023	1
2022	1
2020	3
2017	2
2015	1
2012	1
2011	2
2010	2
2009	1
2006	2
2002	1

View all Acquisitions by Gilead

Recent acquisitions by Gilead

Gilead's most recent acquisition - Tubulis Technologies is a Developer of antibody-drug conjugates for the treatment of cancer, founded in 2015 and located in Munich. Gilead acquired it in April 2026 for a price of $*****.

Here is the list of all acquisitions by Gilead sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Apr 07, 2026	Tubulis Technologies	lhxc	yxpj	22	435
Mar 23, 2026	Ouro Medicines	ggiu	khht	54	550
Feb 23, 2026	Arcellx	upii	wfzt	81	915
Feb 12, 2024	CymaBay Therapeutics	cfcm	fcys	32	896
May 01, 2023	XinThera	nprj	gvnr	30	660